Polypid Ltd (PYPD) Stock Price, Quote & News

Company Profile

PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in precl...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 7 4719 5700

Website: www.polypid.com

Address:

18 Hasivim Street, Petah Tikva, Israel

Finnish_boy Apr. 10 at 2:50 PM

$PYPD Bought more. I will buy next week, week after next week, and week after week after. Three buys potentially until big US partnership news

0 · Reply

Finnish_boy Apr. 10 at 9:39 AM

$PYPD And yes, a big monster in the making. The story hasnt started yet. The company will be massive in 5 years and they know it. The next manufacturing facility will be built in US. I think biggest shareholder gains will happen in a year, looking for SP move from $4 to $15.

0 · Reply

Finnish_boy Apr. 10 at 9:16 AM

$PYPD GLP-1 is just starting point for +50 days release platform. I expect very big partnership in 8-12 months. The preclinical data out in Q3. Lovely catalyst after NDA approval. MAA submission will follow also.

0 · Reply

trademama87 Apr. 9 at 9:08 PM

$PYPD Jan 20: “We are in conversations, advancing conversations with a number of potential partners. Discussions are ongoing... We will announce a US deal in the next few months.” Feb 11: “We are advancing from high level discussions. Due diligence is going on and is more in the details… Around the time that we will be submitting the NDA, we should be close to announcing (partnership)” Mar 31: “U.S. Commercialization Partnership Negotiations on Track” 🔥 Expecting news in April or May.

3 · Reply

Finnish_boy Apr. 9 at 7:52 PM

$PYPD I think US partnership news next week.

1 · Reply

TomiGurArie Apr. 9 at 4:32 PM

$PYPD this might be the one

0 · Reply

PaulWalter Apr. 9 at 2:41 PM

$PYPD been in this before puberty. Still Living on hopium. Management couldn’t close a door.

0 · Reply

Finnish_boy Apr. 9 at 10:29 AM

$PYPD I will buy more today . And then buying every monday little bit. So the longer the partnership news takes, the more money i will make. Ofc i am carrying more risk. Life is hard.

0 · Reply

Finnish_boy Apr. 9 at 8:45 AM

$PYPD This was from late January. Listen 27:00 -28:00. I think partnership deal within a month. After this conference they have been talking that US parnership talks are advancing in late stages. https://www.youtube.com/watch?v=_kMfpIO8UUk&t=1358s

0 · Reply

PaulNipkow Apr. 9 at 8:14 AM

$PYPD a hidden Gem !

0 · Reply

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

Mar 17, 2026, 8:30 AM EDT - 24 days ago

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application

Feb 25, 2026, 8:35 AM EST - 6 weeks ago

PolyPid Announces Participation in Upcoming Investor Conferences

Feb 11, 2026, 7:30 AM EST - 2 months ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Jan 28, 2026, 8:00 AM EST - 2 months ago

PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

Dec 16, 2025, 8:30 AM EST - 4 months ago

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

Dec 3, 2025, 8:30 AM EST - 4 months ago

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

Nov 25, 2025, 8:30 AM EST - 4 months ago

PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025

Nov 12, 2025, 7:30 AM EST - 5 months ago

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 8:30 AM EST - 5 months ago

PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"

Oct 29, 2025, 8:30 AM EDT - 5 months ago

PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

Sep 30, 2025, 8:45 AM EDT - 6 months ago

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

Sep 17, 2025, 8:44 AM EDT - 7 months ago

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

Sep 16, 2025, 8:30 AM EDT - 7 months ago

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

Sep 3, 2025, 8:30 AM EDT - 7 months ago

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Sep 2, 2025, 8:30 AM EDT - 7 months ago

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

Aug 13, 2025, 7:30 AM EDT - 8 months ago

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 8:00 AM EDT - 8 months ago

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

Jul 30, 2025, 8:00 AM EDT - 9 months ago

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

Jul 15, 2025, 8:00 AM EDT - 9 months ago

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

Jun 16, 2025, 7:20 PM EDT - 10 months ago

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

Jun 11, 2025, 9:42 AM EDT - 10 months ago

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 11, 2025, 9:40 AM EDT - 10 months ago

PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 9, 2025, 8:54 AM EDT - 10 months ago

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

Jun 9, 2025, 7:30 AM EDT - 10 months ago

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

Jun 6, 2025, 4:05 PM EDT - 10 months ago

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

May 30, 2025, 10:12 AM EDT - 11 months ago

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout

May 20, 2025, 7:00 AM EDT - 11 months ago

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

May 14, 2025, 7:00 AM EDT - 11 months ago

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 29, 2025, 7:00 AM EDT - 1 year ago

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

Apr 22, 2025, 7:00 AM EDT - 1 year ago

PolyPid to Participate in The Citizens Life Sciences Conference

Mar 11, 2025, 7:00 AM EDT - 1 year ago

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Mar 3, 2025, 7:00 AM EST - 1 year ago

PolyPid to Participate in the 37th Annual ROTH Conference

Feb 12, 2025, 7:00 AM EST - 1 year ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Jan 30, 2025, 7:00 AM EST - 1 year ago

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 29, 2025, 7:00 AM EST - 1 year ago

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

Dec 26, 2024, 10:31 AM EST - 1 year ago

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

KMPR ACVA AVXL

Dec 23, 2024, 7:22 PM EST - 1 year ago

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

Dec 11, 2024, 7:00 AM EST - 1 year ago

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

Nov 29, 2024, 1:05 PM EST - 1 year ago

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Nov 7, 2024, 7:00 AM EST - 1 year ago

PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference

Oct 30, 2024, 8:00 AM EDT - 1 year ago

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024

Oct 21, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

Oct 1, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Sep 3, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Participate in Three Upcoming Fall Investor Conferences

Aug 1, 2024, 8:31 PM EDT - 1 year ago

PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds

Jul 31, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024

Jun 10, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ Phase 3 Trial

May 8, 2024, 7:00 AM EDT - 2 years ago

PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 1, 2024, 7:00 AM EDT - 2 years ago

PolyPid to Participate in Citizens JMP Life Sciences Conference

Finnish_boy Apr. 10 at 2:50 PM

$PYPD Bought more. I will buy next week, week after next week, and week after week after. Three buys potentially until big US partnership news

0 · Reply

Finnish_boy Apr. 10 at 9:39 AM

0 · Reply

Finnish_boy Apr. 10 at 9:16 AM

0 · Reply

trademama87 Apr. 9 at 9:08 PM

3 · Reply

Finnish_boy Apr. 9 at 7:52 PM

$PYPD I think US partnership news next week.

1 · Reply

TomiGurArie Apr. 9 at 4:32 PM

$PYPD this might be the one

0 · Reply

PaulWalter Apr. 9 at 2:41 PM

$PYPD been in this before puberty. Still Living on hopium. Management couldn’t close a door.

0 · Reply

Finnish_boy Apr. 9 at 10:29 AM

$PYPD I will buy more today . And then buying every monday little bit. So the longer the partnership news takes, the more money i will make. Ofc i am carrying more risk. Life is hard.

0 · Reply

Finnish_boy Apr. 9 at 8:45 AM

0 · Reply

PaulNipkow Apr. 9 at 8:14 AM

$PYPD a hidden Gem !

0 · Reply

Finnish_boy Apr. 8 at 7:01 PM

$PYPD Partnership news within a month. Pretty sure we hear the news before Q1 earnings call. And on the call they will tell more about pre-approval marketing strategy and they will reiterate guidance of NDA submission by the end of Q2.

0 · Reply

Finnish_boy Apr. 7 at 9:49 PM

$PYPD If my other stocks jump and this stays below$4.5, i will add on my big position. NDA submission is normally priced in. In this case, i thought it can be decent catalyst if markets would wake up. But i also thought that NDA submission can be "nothing" bc nobody talks about this stock so everyone ignores the NDA submission news also. Lets see US partnership news. I expect the news by the end of April.

1 · Reply

TheSuper Apr. 7 at 3:48 PM

$PYPD in with a starter of 3k shares.

0 · Reply

Finnish_boy Apr. 3 at 2:15 PM

$PYPD Interesting to see who is the partner (medtech or specialty pharma) and what are the terms (how much bigger deal than EU deal +$110M). And label is important thing to follow. In EU they have abdominal label right away, but in US they have only colorectal at first. Label expansion to abdominal should be quite easy. Also, huge potential outside of abdominal, more studies ahead. I think US partnership will be big boost for SP in a couple days/week after the announcement, but i think you can buy the stock still at reasonable price right after the announcement bc stock is totally under radar. Comment below if you have some ideas.

0 · Reply

CARTE_BLANCHE_DEVEREAUX Apr. 3 at 3:02 AM

$PYPD

0 · Reply

Finnish_boy Apr. 2 at 7:44 PM

$PYPD US partnership news happens very likely this month. Latest next month. I listened CEO talking about timing, she meant the first submission. So i expect the news in weeks. They have enough cash until late this year + upfront from US deal. We dont see any extra dilutution in H1 or before NDA approval. They have upped TAM program also. You never know but i think i am right!

2 · Reply

CARTE_BLANCHE_DEVEREAUX Apr. 2 at 3:48 PM

$PYPD $SLS I’m getting asked pretty regularly when we can expect partnership news... and so I am trying to game out PYPD’s timing. They just started a rolling NDA, which means the real FDA clock (Day‑74 letter) only kicks when the file is complete. If the partner wants “early FDA feedback” probably waits for that first formal read, so I’m thinking in terms of a 2–3 month window from completion of the NDA, and realistically a 3–6 month band, not a hard deadline. So the real question for me is whether PYPD can actually bridge to PDUFA without a deal. Cash runway is tight, so they almost NEED an upfront payment from a U.S. partner just to get through NDA review and launch prep. That makes timing and deal structure (size of upfront vs. milestones/royalties etc etc etc) as important as FDA risk. This is still trading well below rNPV. But people aren't entering because of dilution threat... But dilution would be a lot less if people entered.... Sigh.

3 · Reply

OfficialStocktwitsUser Apr. 2 at 12:56 PM

$PYPD RSI: 57.86, MACD: -0.0081 Vol: 0.12, MA20: 4.28, MA50: 4.40 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

robbied61 Apr. 1 at 5:03 PM

$PYPD there cash position is good till September this rolling submission mission had its first green light from fda indicating the beginning of the end roll ing submission will be completed by end of may partner shortly after that approval i january game set and match into the low teens

0 · Reply

PaulNipkow Apr. 1 at 8:46 AM

$PYPD Value for money here ! Hold & Add

1 · Reply

Finnish_boy Mar. 31 at 10:00 PM

$PYPD They already have preferred partner, doing due diligence and negotiating final terms. But not sure when the news are out.

0 · Reply

Finnish_boy Mar. 31 at 9:58 PM

$PYPD How you read this. I think she means this submission, not final submission. But "around the time" and "should be close" are not exact timelines. I think within 2 months very likely, and over 50% chance that by the end of April. This is very big catalyst. Markets cant ignore this one when the news are out. Comment below if some ideas about timing.

1 · Reply

Market Cap	78.62M
Revenue (ttm)	0.00
Net Income (ttm)	-34.17M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.09

Volume	13,900
Avg Vol	51,232
Day's Range	N/A - N/A
Shares Out	19.08M
Stochastic %K	77%
Beta	1.45
Analysts	Strong Sell
Price Target	$12.25